obidoxime
Trade name: toxogonin
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Dec 31, 2021 (NCT05006638)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- AcetylcholinesteraseACTIVATOR
ACHE activator
Chemistry & pharmacology
Loading structure…
SMILES
O/N=C/c1cc[n+](COC[n+]2ccc(/C=N/O)cc2)cc1- Mol. weight
- 288.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL451635 ↗
- ChEMBLCHEMBL291233 ↗
Also known as
- obidoxim
- obidoxime
- obidoxime
- obidoxime
- obidoxime
- obidoxime
- obidoxime
- obidoxime chloride
- toxogonin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05006638 | Phase 4 | Dec 31, 2021 | Ain Shams University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1